Results 81 to 90 of about 178,738 (259)

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro   +15 more
wiley   +1 more source

Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago

open access: yesCardiology and Therapy
Introduction Trinidad & Tobago has the highest prevalence of cardiovascular disease (CVD) in the Caribbean and clopidogrel is a ubiquitously used treatment. Yet, the extent of genetically mediated clopidogrel resistance is unknown.
Daniele Jones   +4 more
doaj   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia   +2 more
wiley   +1 more source

Remote platelet function testing using P-selectin expression in patients with recent cerebral ischaemia on clopidogrel

open access: yesStroke and Vascular Neurology
Background Antiplatelet agents reduce recurrence after cerebral ischaemia but are not effective in all patients, in part because of treatment resistance. The primary aim was to assess the proportion of patients who are insensitive to clopidogrel.
Philip M Bath   +6 more
doaj   +1 more source

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]

open access: yes, 2018
© 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki   +3 more
core   +2 more sources

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli   +17 more
wiley   +1 more source

Is depression a real risk factor for acute myocardial infarction mortality? A retrospective cohort study [PDF]

open access: yes, 2019
Background: Depression has been associated with a higher risk of cardiovascular events and a higher mortality in patients with one or more comorbidities.
Baldo, V.   +7 more
core   +1 more source

Pseudoaneurysms as a complication of stereoelectroencephalography: Case series and clinical recommendations

open access: yesEpilepsia, EarlyView.
Abstract Objective Stereoelectroencephalography (sEEG) is commonly employed in the workup for epilepsy surgery in patients with focal drug‐resistant epilepsy (DRE). Intracranial hemorrhage is a known complication, with reported incidence rates ranging from .9% to 19.1%. Rarely, pseudoaneurysms have been reported in literature as a potential cause. This
Youssra El Khou   +35 more
wiley   +1 more source

PrasugRel versus adjusted high-dose clopidogrel in patients with high on- clopidogrel platelet reactivity: the PECS-HPR randomized, multicenter study [PDF]

open access: yes, 2015
background: Repeated loading doses (LD) of clopidogrel were shown to effectively overcome high on-clopidogrel platelet reactivity (HPR); however, comparison to potent P2Y12-inhibitors is lacking.
Aradi, Dániel
core   +1 more source

Flow Cytometric Profiling Reveals Platelet Dysfunction and Impaired Immune Communication in Acute and Chronic Cerebrovascular Disease

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
Platelets act as sensors linking inflammation and neurovascular health. Flow cytometry revealed reduced PAC‐1 in acute/subacute ICH but elevated in chronic disease, while P‐selectin remained suppressed. T lymphocyte–platelet aggregates declined across groups, indicating disrupted immune crosstalk, and these biomarkers reflect stage‐specific platelet ...
Chih‐Lung Shen   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy